Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus

Table 4

Interdrug differences in terms of adverse events.

	Empagliflozin, (%)	Dapagliflozin, (%)	Canagliflozin, (%)
Chronic or recurring genital yeast infections	41 (66.1)	16 (64.0)	9 (81.8)
Persistent or recurring urinary tract infections	7 (11.3)	3 (12.0)	1 (9.1)
Other adverse events^a	14 (22.6)	6 (24.0)	1 (9.1)

^aPolyuria, nausea, hypotension, dizziness, acute coronary event, worsening of glycemic control, and rapid deterioration of renal function.